Nektar Therapeutics at Cowen Health Care Conference Transcript
Good morning, let's get started. My name is Chris Shibutani, I'm a member of the Cowen Equity Research team of the biotech group. I'm very pleased to have Nektar Therapeutics present with us once again. Yesterday, for those of you who attended our panel on the novel I-O therapeutics, we had few of the world's leading experts Jason Luke, Chuck Drake comment as well as accompanying with the KOL survey's about, a, the significant unmet need that still exists and the vast array of opportunities that are out there. Nothing is simple, and there's no single solution. And therefore, I think having an approach that embraces that complexity, the classic multiple shots on goal and breadth of assets, I think, will be essential as we tackle so many of these dimensions. A company that is very well-positioned to continue to unveil assets and approach strategies to address these needs, Nektar therapeutics here to update us. Jonathan Zalevsky, Chief Scientific Officer, correct? Thanks.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
